Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene, Kaiser Permanente to Conduct Clinical Study for Colon Cancer Dx

NEW YORK, April 28 (GenomeWeb News) - ChondroGene said yesterday that it will partner with Kaiser Permanente of Northern California on a prospective clinical study to evaluate its molecular diagnostic test for colon cancer.

 

The study will compare the results of the company's ColonSentry blood-based colon cancer test to colonoscopy findings in a group of 600 patients from at-risk and confirmed cancer populations.

 

The results of the study will be used to advance development of the test, ChondroGene said, and will "allow Kaiser Permanent to evaluate the test in a patient population."

 

Compared to current stool-based or endoscopic-based screening approaches, "a blood-based test would be more convenient and would likely enhance patient compliance," said T. R. Levin, director of colorectal cancer screening for the Kaiser Permanente Medical Group.

 

The ColonSentry test is the first commercial diagnostic application of ChondroGene's Sentinel Principle molecular diagnostic technology.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.